
Shanghai Pioneer Holding Ltd
1345.HKHKSEHealthcareMedical - Pharmaceuticals
最新数据
HK$2.20
HK$0.00 · 0.00%
1345.HK公司概览
盘中时间采用HKT。市场数据可能有所延迟。
公司概况
公司网站China Pioneer Pharma Holdings Limited operates as an investment holding company, primarily focusing on the marketing, promotion, and distribution of pharmaceutical goods and medical devices within mainland China. The firm maintains an extensive portfolio of pharmaceutical products addressing diverse therapeutic areas, including ophthalmology, pain management, cardiovascular health, immunology, gynecology, and gastroenterology. Its medical device offerings encompass solutions for ophthalmology, orthopedics, dentistry, and wound care. The company supplies its products to a wide client base, including hospitals, various medical institutions, and pharmacies. Additionally, it engages in the sale of supporting tools, leases related equipment, provides dental apparatus, and distributes imported prescription products under license. Established in 1996, China Pioneer Pharma Holdings Limited is headquartered in Shanghai, PRC, and functions as a subsidiary of Pioneer Pharma (BVI) Co., Ltd.
- 行业
- Medical - Pharmaceuticals
- 部门
- Healthcare
- 总部
- CN
- 首席执行官
- Yuewen Yang
- 上市以来
- 2013年11月5日
- 雇员
- 364
市场位置
52周区间
当前HK$2.20,
- 开盘价
- HK$2.20
- 前收盘价
- HK$2.20
- 成交量
- 5.1万
- 1.17× 平均值
- 平均成交量
- 4.36万
- 日均成交量
- 市值
- 25.5亿 HKD
- 贝塔
- -0.16
- 市场参考 1
- 50天平均值
- HK$2.254
- 低于平均水平-2.40%
- 200天平均值
- HK$2.2353
- 低于平均水平-1.58%
财务数据
财务快照
最近十二个月估值与收益率
- 企业价值
- 23.74亿 CNY
- EV/EBITDA
- 13.77×
- 盈利收益率
- 4.68%
- 自由现金流收益率
- 7.72%
盈利能力和效率
- 净资产收益率
- 10.90%
- 资产收益率
- 7.68%
- 投入资本回报率
- 7.99%
财务健康
- 流动比率
- 3.22×
财报历史与展望
- 最新财年每股收益
- 0.099
- 2025财年 · 同比-23.69%
- 最新财年收入
- 12.83亿 CNY
- 2025财年 · 同比-16.17%
年度每股收益趋势
已公布业绩及可用的市场共识预期。
年度营收趋势
已公布业绩及可用的市场共识预期。
1345.HK同业公司
继续GoAI的研究
在 GoAI 中研究1345.HKresearch.disclaimer





